Well before the COVID-19 pandemic struck in early 2020, drug developers were struggling to become more efficient. At industry conferences, executives, regulators, and investigators lauded new approaches, including decentralized trials (DCTs), patient centricity, adaptive study designs, and risk-based central monitoring. Still, uptake lagged.